Is the 2026 Home Health M&A Window Closing? What Fewer Deals and Bigger Checks Mean for Your Exit

Q2 2026 brought fewer home based care closings, but two exceptionally large transactions show that significant capital remains active. This article explains what the deal counts, platform investments, and Enhabit transaction may mean for a smaller agency owner. It also outlines practical steps to improve buyer confidence and reduce the risk of a valuation haircut or delayed closing. The market is selective, but preparation can help owners make a stronger exit decision.

10/19/20267 min read

Home based care agency owner weighing fewer transactions against larger potential deal values.

This article looks at what Q2 2026 home based care deal activity may signal for home health or hospice agency owners considering a sale or succession. It explains why fewer closings do not necessarily mean buyers have left the market, what large transactions can and cannot tell smaller owners about valuation, and how preparation can help protect a deal through diligence.

Quick-Scan Summary

Who this is for

Home health or hospice owners with $2 million to $10 million in revenue
Owners weighing a sale, succession, or strategic partnership in the next 12 to 24 months
Operators who want to understand how market activity and buyer underwriting may affect their exit

Key takeaways

Sixteen home based care transactions closed in Q2 2026, compared with 27 in Q1 2026 and 29 in Q2 2025.
Deal count slowed, but two of the quarter’s largest home based care transactions on record show that large checks are still being written.
The 10.2x Enhabit multiple is not a direct benchmark for a smaller private agency. Scale, compliance, payer mix, leadership depth, and deal context all matter.
Regulatory friction may be making transactions more complex, but one quarter of data does not establish a long term trend.
Organized billing, compliance, financial, and operational records can help reduce buyer uncertainty and protect value through closing.

Market context: fewer closings, large transactions

Mertz Taggart counted 16 home based care transactions closed between April 1 and June 30, 2026. That was down from 27 in Q1 2026 and 29 in Q2 2025. Two additional deals had been announced but had not closed by the end of the quarter.

By segment, hospice and home care each recorded eight closings, while skilled home health recorded six. These segment counts add up to more than 16 because some transactions involved more than one type of service.

Segment counts may overlap when a transaction includes more than one service line. Two additional deals were announced but had not closed by quarter end.

The quarter’s deal structure also shifted:

The figures come from Mertz Taggart’s tracking and definitions for the quarter. The available reports do not provide a separate methodology comparison that would explain differences across data providers, so owners should avoid treating the counts as a universal census of every transaction.

Regulation may be contributing to slower deal execution. Mertz Taggart noted that fraud takedowns, the hospice 36 month rule, a new enrollment moratorium, and enhanced oversight could make transactions more complex to complete. The firm also cautioned that this is one quarter, and the dollar value of the largest deals points to continued investor interest.

Home health, hospice, and home care represented in a simplified transaction market illustration.

What “fewer deals, bigger checks” may mean

Two transactions illustrate the contrast. General Atlantic acquired TEAM Services Group from Alpine Investors for a reported price of about $3 billion. Because the reported figure is a purchase price, not enterprise value, an EBITDA multiple cannot be reliably calculated from the information provided.

Kinderhook Industries completed its take private of Enhabit at an enterprise value of roughly $1.1 billion. The transaction represented 10.2 times EBITDA on $108 million of EBITDA. Enhabit shareholders received $13.80 per share in cash, a 24% premium to the undisturbed share price and nearly 34% above the 60 day average.

At the same time, six new platform investments outnumbered four sponsor backed add ons. That reversed the add on heavy pattern of recent years. It suggests that some buyers are pursuing businesses they can build around, rather than focusing only on acquisitions that expand an existing platform.

Mertz also noted that sponsors are increasingly looking to return capital to limited partners after long holding periods. That may support ongoing interest in transactions. It does not mean every owner will receive a premium offer: buyers still have to see a business they can underwrite, operate, and transition with confidence.

What the Enhabit multiple tells a smaller owner

The Enhabit transaction is useful context, not a valuation formula for a private agency. Mertz cautioned against leading with multiples: Enhabit was a billion dollar public company, and its 10.2 times EBITDA transaction included a substantial premium to its public market price.

For a $2 million to $10 million revenue home health or hospice agency, buyers will assess the specific business and its risks. They will examine whether earnings are supportable, whether billing and compliance records are clear, whether payer and referral relationships are durable, and whether clinical and operational leadership can function without the owner at the center of every decision.

Consider an illustrative valuation scenario. If an agency has $700,000 in normalized EBITDA, then:

These are example calculations, not market quotes or a prediction of what a particular agency will receive. The $1.05 million difference shows why earnings quality and buyer confidence matter. If a buyer cannot verify the financial picture or sees unresolved operational risk, the effect may be a lower valuation, more restrictive terms, or a longer process.

Agency owner and buyer reviewing organized financial and compliance records.

Is the exit window closing?

There are two reasonable readings of the Q2 data.

The cautious reading: fewer closed deals can mean a more difficult path to closing. Regulatory complexity may lengthen diligence, and enhanced oversight can lead buyers to examine billing, documentation, enrollment, ownership, and compliance more closely. A signed agreement is not the same as a completed transaction.

The more optimistic reading: capital is still moving into the sector, and buyers may value clean, transferable agencies in a market where fewer businesses are getting to the finish line. The return timing of long held investments may also keep sponsors focused on acquisitions and exits.

Mertz’s advice for owners considering a process over the next 12 to 24 months is direct: “Diligence around billing and compliance has only intensified, especially in the enhanced oversight states, and the sellers who invest early in getting their house in order are the ones who hold their value all the way through to close.”

That is not a promise of a particular sale price. It is a practical point about avoiding preventable surprises when a buyer begins testing the business’s records and assumptions.

What helps a deal get across the line

A buyer underwrites more than reported earnings. The buyer needs to understand how those earnings were generated, whether they can continue, and what must change after a transaction.

Start with the records a buyer is likely to test:

Billing and compliance: Organize claims support, clinical documentation, audit history, corrective actions, and compliance policies. Resolve discrepancies where possible and be ready to explain open issues.
Financials: Reconcile financial statements to tax returns, bank records, payroll, and billing reports. Document owner related expenses and any proposed normalization adjustments.
Operations and ownership: Keep licenses, enrollment information, ownership records, contracts, and organization charts current. Understand which changes may require review or approval.
Leadership continuity: Document key processes and reduce reliance on the owner for daily decisions, referral relationships, or institutional knowledge.
Diligence materials: Prepare a secure, well organized data room so a buyer can find answers without repeated requests and avoidable delays.

The goal is not to make an agency look perfect. It is to make its strengths, risks, and operating model understandable. A buyer can evaluate a known issue more constructively than a surprise discovered late in diligence.

A note for hospice owners

Hospice tied with home care for the most closed transactions in Q2, with eight. Hospice owners should also take the regulatory concerns in the market seriously, particularly the 36 month rule and enhanced oversight referenced by Mertz Taggart. These developments do not mean every hospice transaction is blocked, but they can add questions and complexity to ownership, enrollment, and closing processes.

For hospice owners, the same preparation principles apply: keep billing and clinical records organized, understand the status of compliance matters, and reduce dependence on one owner or leader. Home health owners face their own scrutiny, but should not assume hospice rules apply to them or that hospice specific requirements are interchangeable with home health requirements.

Agency owner preparing a succession handoff with organized records and care materials.

So what should you do now?

Compare your monthly financial reporting with billing and operational data, and investigate material differences.
Make a short list of unresolved compliance, enrollment, or documentation issues and assign responsibility for each.
Document the decisions, relationships, and processes that currently depend on you personally.
If you may pursue a sale or succession within 12 to 24 months, start organizing diligence materials before you need them.

Plain-Language Glossary

EBITDA: A measure of operating earnings before interest, taxes, depreciation, and amortization.
Normalized EBITDA: Earnings adjusted to reflect costs and income expected to continue under a new owner.
Multiple: A number applied to EBITDA to estimate enterprise value. For example, 4.5 times $700,000 equals $3.15 million.
Platform investment: An investment in a business intended to serve as a base for future growth or acquisitions.
Add on: An acquisition added to an existing platform or operating company.
Take private: A transaction that moves a publicly traded company into private ownership.
Enterprise value: A measure of the value of a business that includes equity value and debt, subject to deal terms.
Premium: The amount a buyer pays above a reference share price or other benchmark.
Enhanced oversight: Increased regulatory attention or review applied to certain providers or circumstances.
Limited partner, or LP: An investor in a private investment fund that provides capital but generally does not manage its day to day operations.

Explore a potential sale or partnership

Senate Healthcare LLC is the buyer and strategic partner pursuing home health or hospice agency acquisitions. We are not a broker or advisor. If you are considering a sale, succession, or partnership, we welcome a confidential conversation about a potential acquisition and the steps that may reduce risk and support a clearer outcome. Your agency does not need to be perfectly positioned today to start that discussion.

Resources:

Unlock Your 30-Minute Agency Succession Review

Maybe you're ready to expand your reach, or perhaps it's time to consider your legacy and the future of your business. Either way, it all begins with a conversation. Schedule a confidential, no-obligation call to explore what the future might hold for you and your business.

Complete the form, and we'll reach out for a chat...